Search results
Results From The WOW.Com Content Network
Novartis AG. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Calpol was launched in 1959 by English pharmaceutical company, Calmic Ltd, based in Crewe, Cheshire; the company's name was an abbreviation of Cheshire and Lancashire Medical Industries Corporation, which moved from Lancashire to Crewe Hall in 1947. [6] The Calpol brand name is likely a combination of 'Calmic' and 'paracetamol'. [7]
He spent 8 years working in Novartis Vaccines, at the time a non-profit division focused on developing vaccines for children and patients around the world and served as the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17]
By Sriparna Roy. (Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease, the health ...
Rank Drug Main indication Trade name 2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 apixaban
Diversified health care giant Novartis has had a fairly strong year so far, with its stock price outperforming industry peers GlaxoSmithKline , AstraZeneca, Pfizer, and Merck by a wide margin ...
During its development by Novartis, Entresto was known as LCZ696. [9] It was approved under the FDA's priority review process on 7 July 2015. [11] It was also approved in Europe in 2015. [7] In 2022, Novartis sold its India marketing rights of Sacubitril Valsartan to JB Pharma, under the brand name Azmarda. [35]